Youling Gong

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming

Feifei Na, Xiangyu Pan, Jingyao Chen et al. · Nature Cancer · 2022 · 120 citations · Full text

Medicine, Molecular Biology, Oncology +14

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment

Xin Tang, Yuan Li, Wei‐Feng Yan et al. · Frontiers in Oncology · 2021 · 33 citations · Full text

Medicine, Oncology, Radiology +16

Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection

Weigang Xiu, Yin Huang, Yanying Li et al. · Anti-Cancer Drugs · 2021 · 14 citations · Full text

Medicine, Biostatistics, Oncology +17

194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results

Yuwen Zhang, Yun Xie, Youling Gong et al. · ESMO Open · 2024 · 12 citations · Full text

Medicine, Oncology, Radiation Oncology +17